卡瑞利珠单抗致食管癌患者多发性肌炎伴重症肌无力1例  

One case of myositis with myasthenia gravis caused by camrelizumab in esophageal cancer

作　　者：王英南[1] 范垚 孙芳毅[2] 韩颖[3] 葛胜梅[4] 张风宾[1] 张瑞星[1] WANG Yingnan;FAN Yao;SUN Fangyi;HAN Ying;GE Shengmei;ZHANG Fengbin;ZHANG Ruixing(Department of Gastroenterology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,Heibei Province,China;Department of cardiovascular Medicine,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,Heibei Province,China;Department of Neurology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,Heibei Province,China;ICU,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,Heibei Province,China)

机构地区：[1]河北医科大学第四医院消化内科,河北石家庄050011 [2]河北医科大学第四医院心血管内科,河北石家庄050011 [3]河北医科大学第四医院神经内科,河北石家庄050011 [4]河北医科大学第四医院重症监护室,河北石家庄050011

出　　处：《肿瘤》2023年第2期157-160,共4页Tumor

基　　金：河北省重点研发计划项目(21377759D)

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在肿瘤领域广泛应用,显示出了巨大的优势和发展潜力,但在发挥治疗作用的同时伴随着一系列免疫相关不良反应的发生。其中,肌炎是一个潜在的致命不良事件而引发关注。本文报道1例使用国产PD-1抑制剂注射用卡瑞利珠单抗用于治疗晚期食管癌患者而诱发多发性肌炎伴重症肌无力(myasthenia gravis,MG),同时出现肌无力危象等,经多学科协作积极抢救后转危为安的病例。Although immune checkpoint inhibitors(ICIs)are widely used in cancer therapy,showing great advantages and development potential,it is accompanied by a series of immune-related adverse reactions,of which myositis is a potentially fatal adverse event,which has attracted great attention.Herein,we reported a case of advanced esophageal cancer with myositis after treatment with camrelizumab,which was characterized by myasthenia gravis(MG)with myasthenic crisis,and recovered after active rescue by multidisciplinary cooperation.

关 键 词：免疫检查点抑制剂 肌炎 重症肌无力 食管癌 

分 类 号：R969[医药卫生—药理学]